IF TRC4186 (oral gavage, 10–20 mg/kg/day for 8 weeks, based on Torrent Pharmaceuticals preclinical dosing), administered as a single agent and then in sequential combination with a glucosepane-targeted intervention (synthetic glucosepane-cleaving small molecule or bacterially derived enzymatic candidate from Spiegel lab chemical biology pipeline), is applied to aged male and female C57BL/6J mice (22–24 months, both sexes), with crosslink-type-specific aortic biochemistry measured in parallel with non-invasive Doppler pulse wave velocity (PWV),

THEN TRC4186 monotherapy will produce a statistically significant but mechanistically incomplete reduction in aortic PWV (~15–25% decrease from aged-vehicle baseline, consistent with partial crosslink reversal), and post-mortem aortic tissue will show selective reduction of methylglyoxal-derived crosslinks (MOLD, GOLD, quantified by LC-MS) with no significant change in glucosepane abundance (quantified by immunoassay or LC-MS/MS), and the residual PWV elevation above young-reference values will be positively correlated with remaining glucosepane burden,

BECAUSE the following causal chain is operative:

1. TRC4186 retains the N-phenacylthiazolium pharmacophore of alagebrium (ALT-711) and acts by nucleophilic attack at the C2 position of the thiazolium ring on α-dicarbonyl crosslink structures, theoretically cleaving C–C bonds in MOLD and GOLD adducts formed from methylglyoxal condensation with lysine residues on aortic collagen — (thiazolium C2 nucleophile cleaves alpha-diketone crosslinks)[Deshpande et al., Cardiovascular Diabetology, 2017, as cited in evidence set].

2. TRC4186's superior oral bioavailability and extended plasma half-life relative to ALT-711 allow sustained therapeutic concentrations across the collagen turnover timescale, overcoming the primary pharmacokinetic failure mode of alagebrium — (TRC4186 achieves superior pharmacokinetics and potency in diabetic rat models)[Gupta et al., American Journal of Hypertension, 2012, as cited in evidence set].

3. The dominant age-related collagen crosslinks in short-lived rodents (C57BL/6 lifespan ~24–30 months) are distinct from those in long-lived humans; murine aortic collagen accumulates methylglyoxal-derived adducts (MOLD, GOLD) as major structural crosslinks, while glucosepane — which requires decades to accumulate to pathological levels — does not reach human-equivalent concentrations in mice — (species-specific AGE accumulation differences mean murine arterial stiffness is driven by distinct crosslinks from glucosepane-dominant human aging)[Spiegel et al., JACS 2015 and Science 2015, as cited in evidence set].

4. Cleavage of MOLD/GOLD crosslinks by TRC4186 will partially restore collagen fibril sliding and reduce passive structural stiffness, measurably reducing aortic PWV; however, because glucosepane is a structurally distinct imidazolone ring compound — chemically stable and resistant to thiazolium chemistry — residual glucosepane cros...

SENS category: GlycoSENS